Alpha-GPC and the Liver and Kidneys: Is It Safe?
Alpha-GPC (L-alpha-glycerylphosphorylcholine, also called choline alfoscerate) is used in "focus" supplements and some pre-workouts as a source of choline. Questions about whether it burdens the liver or kidneys come up regularly. Our editorial team looked at how the body handles it, what toxicology and clinical studies show, and where real uncertainty remains.
What alpha-GPC is and how it is metabolised
Alpha-GPC is a naturally occurring choline compound found in small amounts in foods and in breast milk. After ingestion it is broken down into choline and glycerophosphate. Choline is then used to make acetylcholine, a neurotransmitter involved in memory and muscle activation, and phosphatidylcholine, a key component of cell membranes.
The liver plays a central role in choline handling. It uses choline to build phosphatidylcholine, which is needed to package and export fat from the liver as lipoproteins. This is why choline deficiency, rather than choline intake, is linked to fat accumulation in the liver.
Zeisel and da Costa described how inadequate choline intake in human studies led to fatty liver and muscle damage markers that reversed when choline was restored. In that sense, appropriate choline intake supports rather than threatens liver health.
Choline and its metabolites are cleared partly via the kidneys. In people with normal kidney function, this is not a burden at supplement doses, but kidney disease changes the picture, as discussed below.
What toxicology and clinical trials show
A formal safety assessment of alpha-GPC as a food ingredient, published by Brownawell and colleagues, reviewed acute, subchronic and genotoxicity studies in animals. It reported a low order of toxicity and no specific liver or kidney damage at doses well above those consumed by people.
In medicine, choline alfoscerate is used in some European countries for cognitive decline. A multicentre trial by De Jesus Moreno Moreno in mild to moderate Alzheimer's disease used 1,200 mg per day for 180 days, and reported good tolerability with no pattern of liver or kidney adverse effects.
In sports research, doses have been lower and shorter. Ziegenfuss and colleagues gave 600 mg before resistance exercise, and Bellar and co-workers used 600 mg per day for six days; neither study reported organ-related adverse events. Parker and colleagues tested alpha-GPC on mood, cognition and power with similar tolerability.
Reported side effects in trials were mostly mild: headache, heartburn, dizziness, insomnia and occasional skin rash.
| Source of data | Dose range studied | Liver/kidney findings |
|---|---|---|
| Animal toxicology | Far above human intake | No specific organ toxicity reported |
| Clinical trial in dementia | 1,200 mg/day for 6 months | Well tolerated |
| Sports studies | Around 600 mg, days to weeks | No organ-related adverse events reported |
| Long-term use in healthy athletes | — | Not studied |
The TMAO and stroke-risk question
The most debated safety issue concerns not the liver or kidneys directly but cardiovascular risk. Gut bacteria can convert choline into trimethylamine, which the liver oxidises to trimethylamine N-oxide (TMAO). Work by Wang and colleagues linked higher TMAO to atherosclerosis in animal models and human cohorts.
In 2021, Lee and co-authors analysed Korean national health data and reported that people prescribed alpha-GPC had a higher risk of stroke over ten years than non-users. This was an observational study, and the people receiving alpha-GPC were older and often had cognitive complaints, so confounding is likely. Even so, it was a signal worth taking seriously.
The kidneys are relevant here because TMAO is excreted in urine. In chronic kidney disease, TMAO levels rise substantially, so people with reduced kidney function may be more exposed to this pathway.
For a healthy young athlete using alpha-GPC occasionally at modest doses, the absolute risk implied by these data is uncertain and probably small. For people with existing cardiovascular or kidney disease, caution is clearly justified.
Who should be careful
Based on current data, several groups should not use alpha-GPC without medical advice. The list reflects biological plausibility and gaps in evidence rather than proven harm.
People with chronic kidney disease are the first group, because of reduced clearance of choline metabolites and higher baseline TMAO.
People with established cardiovascular disease, previous stroke or multiple risk factors should also discuss it with their doctor given the observational stroke-risk signal.
Finally, the regulatory status of nootropic ingredients under UK and EU novel food rules is not always clear-cut, so product quality and labelling can vary. Choosing reputable, tested products is sensible, and pregnant or breastfeeding women should avoid it due to lack of data.
- chronic kidney disease or reduced eGFR;
- previous stroke, heart disease or high cardiovascular risk;
- pregnancy and breastfeeding;
- use of anticholinergic or cholinergic medicines (possible interactions).
Editorial conclusions
Available toxicology and clinical data do not show direct liver or kidney damage from alpha-GPC at doses used in research. Choline itself is essential for normal liver function.
The genuine open question concerns the TMAO pathway and a possible link with stroke risk, which matters most for older people and those with cardiovascular or kidney disease.
For healthy adults, staying within the doses used in studies and avoiding continuous high-dose use are reasonable precautions; for anyone with kidney or heart conditions, the decision belongs with a doctor.
Readers interested in this area may also like our articles on choline in sports nutrition, on what TMAO is and why it is discussed, and on nootropic supplements for training focus.
References
- Brownawell AM, Carmines EL, Montesano F. Safety assessment of AGPC as a food ingredient. Food Chem Toxicol. 2011;49(6):1303–1315.
- De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178–193.
- Bellar D, LeBlanc NR, Campbell B. The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr. 2015;12:42.
- Ziegenfuss T, Landis J, Hofheins J. Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. J Int Soc Sports Nutr. 2008;5(Suppl 1):P15.
- Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63.
- Lee G, Choi S, Chang J, et al. Association of L-α glycerylphosphorylcholine with subsequent stroke risk after 10 years. JAMA Netw Open. 2021;4(11):e2136008.
- Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009;67(11):615–623.
